Osimert (Osimertinib) 80 mg
Osimert (Osimertinib 80 mg) is a third-generation EGFR tyrosine kinase inhibitor (TKI), representing the most advanced standard of care for lung cancer.
Manufacturer: Everest Pharmaceuticals. A generic equivalent of Tagrisso.
The "Resistance Breaker":
Osimertinib is specifically designed to target both the initial EGFR mutation and the acquired T790M resistance mutation. It works when older drugs (like Gefitinib or Erlotinib) stop working.
✅ Key Benefit (CNS Activity): Unlike its predecessors, Osimert has high penetration into the brain, making it highly effective against CNS metastases.
Indicated for the treatment of adult patients with metastatic Non-Small Cell Lung Cancer (NSCLC):
- 🧬 Second-line: For patients whose disease has progressed on other EGFR TKI therapy and who have developed the T790M mutation (confirmed by test).
- 🚀 First-line: As an initial treatment for patients with common EGFR mutations (Exon 19 deletion or Exon 21 L858R).
Standard Dosage: One 80 mg tablet once daily.
⚠️ Administration Instructions:
- Take at the same time each day, with or without food.
- Difficulty Swallowing? The tablet can be dispersed in 50 mL of non-carbonated water. Do not crush. Stir until dispersed and drink immediately. Rinse the glass with more water and drink to ensure the full dose is taken.
🚫 Interaction Warning: Avoid St. John's Wort and strong CYP3A inducers.
- Pregnancy and breastfeeding (embryo-fetal toxicity).
- History of QTc interval prolongation (heart rhythm issues).
- Hypersensitivity to the active substance.
Generally better tolerated than 1st generation TKIs, but monitor for:
- Cardiac Issues: Decreased Left Ventricular Ejection Fraction (LVEF) or QTc prolongation.
- Skin & Nails: Rash, dry skin, paronychia (nail infections).
- Pulmonary: Interstitial Lung Disease (ILD)/Pneumonitis (rare but serious).
- Diarrhea.
Similar products
What Customers Say
No reviews yet
Your review can be the first!